Detalles de la búsqueda
1.
Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
Circulation
; 141(17): 1360-1370, 2020 04 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32098501
2.
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Circulation
; 140(20): 1613-1622, 2019 11 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31542942
3.
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 377(13): 1228-1239, 2017 09 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28910237
4.
Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Diabetes Obes Metab
; 20(1): 165-172, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28685973
5.
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Diabetes Obes Metab
; 20(6): 1515-1519, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29316164
6.
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Diabetes Obes Metab
; 20(6): 1520-1525, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29573139
7.
Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
Diabetes Obes Metab
; 20(4): 898-909, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29193561
8.
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Am Heart J
; 187: 1-9, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28454792
9.
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Diabetes Obes Metab
; 19(7): 979-988, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28205322
10.
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
N Engl J Med
; 369(14): 1317-26, 2013 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-23992601
11.
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
Am Heart J
; 174: 103-10, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26995376
12.
Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.
Circulation
; 138(22): 2576-2578, 2018 11 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30571356
13.
Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies.
Toxicol Pathol
; 40(1): 18-32, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22131108
14.
The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
Am Heart J
; 162(5): 818-825.e6, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22093196
15.
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
Diabetes Care
; 43(2): 446-452, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31757838
16.
Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).
Diabetes Care
; 42(6): 1075-1080, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31010875
17.
Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
Diabetes Care
; 41(11): 2346-2352, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30213882
18.
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
Diabetes Care
; 41(10): 2136-2146, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30082326
19.
Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.
J Am Heart Assoc
; 7(19): e009304, 2018 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30371301
20.
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Lancet Diabetes Endocrinol
; 6(2): 105-113, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29221659